Ken Griffin Larimar Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,100 shares of LRMR stock, worth $96,641. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,100

Previous 36,500 33.97%

Holding current value

$96,641

Previous $264,000 40.53%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.3 - $10.68 $218,093 - $369,720	34,618 Added 826.4%	38,807 $254,000
Q2 2024 Aug 14, 2024	SELL	$6.33 - $9.89 $7.34 Million - $11.5 Million	-1,160,070 Reduced 99.64%	4,189 $30,000
Q1 2024 May 15, 2024	BUY	$4.2 - $13.28 $2.02 Million - $6.4 Million	481,900 Added 70.62%	1,164,259 $8.84 Million
Q4 2023 Feb 14, 2024	SELL	$2.35 - $4.71 $697,543 - $1.4 Million	-296,827 Reduced 30.31%	682,359 $3.1 Million
Q3 2023 Nov 14, 2023	SELL	$3.08 - $4.49 $608,204 - $886,635	-197,469 Reduced 16.78%	979,186 $3.87 Million
Q2 2023 Aug 14, 2023	BUY	$3.13 - $5.27 $1.57 Million - $2.64 Million	500,217 Added 73.95%	1,176,655 $3.68 Million
Q1 2023 May 15, 2023	BUY	$4.0 - $6.68 $464,284 - $775,354	116,071 Added 20.71%	676,438 $3.06 Million
Q4 2022 Feb 14, 2023	BUY	$2.73 - $5.08 $1.49 Million - $2.77 Million	544,766 Added 3491.87%	560,367 $2.31 Million
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.64 $2,945 - $7,007	1,925 Added 14.08%	15,601 $50,000

Others Institutions Holding LRMR

# of Institutions

128

Shares Held

67.3M

Call Options Held

280K

Put Options Held

76.3K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $174M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account